Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7586 USD | +0.89% | +12.95% | +2.10% |
Business Summary
Number of employees: 55
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Difelikefalin-based Product
100.0
%
| 42 | 100.0 % | 21 | 100.0 % | -49.92% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 42 | 100.0 % | 21 | 100.0 % | -49.92% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 06/18/06 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 12/22/12 |
Scott Terrillion
CMP | Compliance Officer | 61 | 01/16/01 |
Iris Francesconi
IRC | Investor Relations Contact | - | - |
Beth Weinberg
LAW | General Counsel | - | - |
Richard Makara
AUD | Comptroller/Controller/Auditor | 54 | 01/14/01 |
Eric J. Vandal
PRN | Corporate Officer/Principal | - | 02/14/02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 01/10/01 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 16/14/16 |
Helen Boudreau
BRD | Director/Board Member | 58 | 02/23/02 |
Chief Executive Officer | 54 | 06/18/06 | |
Susan Shiff
BRD | Director/Board Member | 63 | 26/20/26 |
Lisa von Moltke
BRD | Director/Board Member | 65 | 01/22/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 54,667,079 | 46,776,193 ( 85.57 %) | 0 | 85.57 % |
Company contact information
CARA Therapeutics, Inc.
400 Atlantic Street Suite 500
06901, Stamford
+203 406 3700
http://www.caratherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.10% | 41.1M | |
-4.14% | 86.85B | |
+2.76% | 40.16B | |
-16.48% | 31.28B | |
+57.86% | 25.27B | |
-13.58% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.18% | 7.94B |
- Stock Market
- Equities
- CARA Stock
- Company Cara Therapeutics, Inc.